Mahadi Baig

Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC

Byoung Chul Cho, Shun Lu, Enriqueta Felip et al. · New England Journal of Medicine · 2024 · 375 citations · Full text

Medicine, Oncology, Pharmacology +14

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +16

Prolonged duration of response in lenvatinib responders with thyroid cancer

Andrew G. Gianoukakis, Corina E. Dutcus, Nicolas Batty et al. · Endocrine Related Cancer · 2018 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC

James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi et al. · New England Journal of Medicine · 2025 · 85 citations

Medicine, Oncology, Pharmacology +15

Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

James W.F. Catto, Ben Tran, Morgan Rouprêt et al. · Annals of Oncology · 2023 · 78 citations · Full text

Medicine, Oncology, Pharmacology +13